Lawsuit filed for Investors in shares of Acer Therapeutics Inc. (NASDAQ: ACER)
A lawsuit was filed on behalf of investors in Acer Therapeutics Inc. (NASDAQ: ACER) shares over alleged securities laws violations
Investors who purchased shares of Acer Therapeutics Inc. (NASDAQ: ACER) have certain options and for certain investors are short and strict deadlines running. Deadline: August 30, 2019. NASDAQ: ACER investors should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
Newtown, MA based Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Acer Therapeutics Inc’s pipeline includes, inter alia, EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (“vEDS”) in patients with a confirmed type III collagen mutation.
In 2004, the French research hospital, Assistance Publique—Hôpitaux de Paris, Hôpital Européen Georges Pompidou (“AP-HP”), published data on vEDS patients. Based on AP-HP’s research, investigators began assessing the preventive effect of celiprolol for major cardiovascular events in patients suffering from vEDS “through a multicenter, prospective, randomized, open trial with blinded evaluation of clinical events” (the “Ong Trial”). The Ong Trial was composed of fifty-three participants “randomized at eight centers in France and one center in Belgium.” The Ong trial’s results were published on October 30, 2010.
On December 13, 2016, Acer Therapeutics Inc. (“Private Acer”)—a private Delaware corporation and Acer’s predecessor—announced that it had obtained exclusive rights to NDA-enabling clinical data from AP-HP for the use of celiprolol in treating vEDS. Specifically, Private Acer had signed an agreement with AP-HP, which granted exclusive rights to access and use data from the Ong Trial. Private Acer announced it would use this data to support its New Drug Application (“NDA”) for celiprolol in the treatment of vEDS.
On September 19, 2017, Private Acer announced that it had closed a merger with Opexa Therapeutics, Inc. (“Opexa”), a publicly-traded Texas pharmaceutical corporation, whereby Private Acer survived as a wholly-owned subsidiary of Opexa (the “Opexa Merger”). Following the Opexa Merger, Opexa changed its name to Acer Therapeutics Inc and Private Acer’s management took control of the combined company. Immediately prior to the Opexa Merger, Opexa’s Board of Directors and Neil K. Warma (“Warma”), Opexa’s then-President, Chief Executive Officer (“CEO”), Acting Chief Financial Officer, and Secretary, resigned.
On September 21, 2017, Acer Therapeutics Inc began trading on the NASDAQ under the ticker symbol “ACER.”
On December 26, 2018, Acer Therapeutics Inc announced that the U.S. Food and Drug Administration (“FDA”) had accepted the Company’s NDA for EDSIVO for the treatment of vEDS in patients with a confirmed type III collagen mutation, as well as the FDA’s grant of priority review of the NDA and an assigned Prescription Drug User Fee Act (“PDUFA”) target action date of June 25, 2019.
On June 25, 2019, Acer Therapeutics Inc issued a press release titled “Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO™ (celiprolol) in vEDS Patients” (the “June 2019 Press Release”). In the June 2019 Press Release, Acer disclosed receipt of a Complete Response Letter (“CRL”) from the FDA regarding its NDA for EDSIVO for the treatment of vEDS. Acer advised investors that “[t]he CRL states that it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS” and that “Acer plans to request a meeting to discuss the FDA’s response.”
That same day, news sources reported that the small group size of the Ong Trial had raised questions among experts about the adequacy of EDSIVO’s trial results.
Shares of Acer Therapeutics Inc. (NASDAQ: ACER) declined to as low as $3.27 per share on June 28, 2019.
The plaintiff claims that between September 25, 2017 and June 24, 2019, the Defendants made false and/or misleading statements and/or failed to disclose that Acer lacked sufficient data to support filing EDSIVO’s NDA with the FDA for the treatment of vEDS, that the Ong Trial was an inadequate and ill-controlled clinical study by FDA standards, and was comprised of an insufficiently small group size to support EDSIVO’s NDA, that consequently, the FDA would likely reject EDSIVO’s NDA, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.
Those who purchased shares of Acer Therapeutics Inc. (NASDAQ: ACER) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North
San Diego, CA 92108
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors in shares of Acer Therapeutics Inc. (NASDAQ: ACER) here
News-ID: 1810631 • Views: 272
More Releases from Shareholders Foundation
Investigation announced for NYSE: COF Investors over possible Wrongdoing at Capi …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Capital One Financial Corporation. Investors who are current long term investors in Capital One Financial Corporation (NYSE: COF) shares, have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: COF stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Acadia Healthcare Company Inc …
An investigation was announced for investors in shares of Acadia Healthcare Company Inc (NASDAQ: ACHC) concerning potential breaches of fiduciary duties by certain directors at Acadia Healthcare Company Inc. Investors who purchased shares of Acadia Healthcare Company Inc (NASDAQ: ACHC) and currently hold any of those NASDAQ: ACHC shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554. The investigation by a law firm
Investigation for Investors in shares of PlayAGS, Inc. (NYSE: AGS) announced
An investigation was announced concerning potential securities laws violations by PlayAGS, Inc. in connection with certain financial statements. Investors who purchased shares of PlayAGS, Inc. (NYSE: AGS), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of PlayAGS, Inc. (NYSE: AGS) concerning whether a series of statements
Lawsuit filed for Investors in shares of Spirit AeroSystems Holdings, Inc. (NYSE …
An investor, who purchased shares of Spirit AeroSystems Holdings, Inc. (NYSE: SPR), filed a lawsuit over alleged violations of Federal Securities Laws by Spirit AeroSystems Holdings, Inc. Investors who purchased shares of Spirit AeroSystems Holdings, Inc. (NYSE: SPR) have certain options and for certain investors are short and strict deadlines running. Deadline: April 10, 2020. NYSE: SPR investors should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 -
More Releases for Acer
Tablets Market Is Booming Worldwide | Amazon, Lenovo, Acer, Insignia, Asus
The Qualitative research study accompanied by ORBIS RESEARCH titled on “Global Tablets Market describing the Product / Business Scope, Overview and outlook from 2019 to 2025”. In this Research Report provides primary and secondary data for studies, the scope of the product and vendor briefings. The market Study is segmented by key regions which are accelerating the marketization and study is segmented by products type, status, size, trends, key players,
Global Smart Displays Market 2019 - ACER, Panasonic, TCL, Changhong, Konka
The smart display is a portable LCD display with a touch screen that ACTS as a PC thin client through a wi-fi connection. In 2019, the market size of Smart Displays is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$
Gaming Laptop Market Is Booming Worldwide | Acer, ASUS, Dell
A new independent 119 page research with title 'Global Gaming Laptop Market Report 2018' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions and important players/vendors such as Acer, ASUS, Dell, MSI, ORIGIN PC, AORUS, CLEVO, Eluktronics, EVGA, Gigabyte Technology, HP, Lenovo, Razer USA, XOTIC PC With n-number of tables and figures examining the Gaming Laptop Market, the research gives you a
Hybrid PC Market: Asus, HP, Lenovo, Sony, Acer
MarketResearchReports.Biz has recently announced the Latest industry research report on: "Global Hybrid PC Market" : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts. This report presents the worldwide Hybrid PC market size (value, production and consumption), splits the breakdown (data status 2013-2018 and forecast to 2025), by manufacturers, region, type and application. This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities
Global Refurbished Computer Equipment Market 2017 : Apple, HP, Dell, Acer
Refurbished Computer Equipment Market 2017 A market study based on the " Refurbished Computer Equipment Market " across the globe, recently added to the repository of Market Research, is titled ‘Global Refurbished Computer Equipment Market 2017’. The research report analyses the historical as well as present performance of the worldwide Refurbished Computer Equipment industry, and makes predictions on the future status of Refurbished Computer Equipment market
Global Wireless Projector Market 2017 : DELL, Panasonic, Acer, CASIO, ASUS
A market study based on the "Wireless Projector Market" across the globe, recently added to the repository of Market Research, is titled ‘Global Wireless Projector Market 2017’. The research report analyses the historical as well as present performance of the worldwide Wireless Projector industry, and makes predictions on the future status of Wireless Projector market on the basis of this analysis. Get Free Sample Copy of Wireless Projector Report Here :